Neuropharmacology of Levetiracetam as Anti-epileptic Medication

Abstract

United state food and drug administration approved Levetiracetam on 30th November 1999 for the use as adjuanctive therapy in the treatment of partial onset seizures in adults with epilepsy. Therapeutic indications of Levetiracetam includes monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy. Levetiracetam is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents, children and infants from 1 month of age with epilepsy, in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy, in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy. This article describes the pharmacological aspects of Levetiracetam that will helful to health professionals.